ASX:PAB

Patrys Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume250,000 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive PAB News and Ratings via Email

Sign-up to receive the latest news and ratings for Patrys and its competitors with MarketBeat's FREE daily newsletter.

About Patrys

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates live cell nuclei and inhibits mechanisms of DNA repair in target cancer cells. The company also focuses on developing PAT-DX1 as a treatment for metastatic triple negative breast cancer and glioblastoma. In addition, it engages in developing PAT-SC1's target/antigen CD55PAT-SC1, an isoform of the membrane-bound CD55 for the treatment of gastric cancer. Patrys Limited has a collaborative research program with Imagion Biosystems Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis. The company was founded in 2006 and is based in South Melbourne, Australia.

Patrys Limited (ASX:PAB) Insider James Campbell Purchases 9,000,000 Shares
September 7, 2021 | americanbankingnews.com

Key Things To Understand About Patrys' (ASX:PAB) CEO Pay Cheque
September 1, 2021 | finance.yahoo.com

Will Patrys (ASX:PAB) Spend Its Cash Wisely?
September 1, 2021 | finance.yahoo.com

Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI - Insight
September 1, 2021 | finance.yahoo.com

Here's Why We're Not At All Concerned With Patrys' (ASX:PAB) Cash Burn Situation
September 1, 2021 | finance.yahoo.com

Patrys (ASX:PAB) Is In A Good Position To Deliver On Growth Plans
May 15, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange ASX
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Current SymbolASX:PAB
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.patrys.com
Phone61 3 9692 7222
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$1.34 million
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow2.40
Book ValueA$0.01 per share
Price / BookN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.27 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Patrys.

4.7 Community Rank

Outperform Votes
Patrys has received 18 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Patrys has received 8 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Patrys has received 69.23% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Patrys and other stocks. Vote “Outperform” if you believe PAB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PAB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Patrys does not currently pay a dividend.
Dividend Growth
Patrys does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Patrys insiders have bought more of their company's stock than they have sold. Specifically, they have bought A$63,000.00 in company stock and sold A$0.00 in company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Patrys (ASX:PAB) Frequently Asked Questions

What stocks does MarketBeat like better than Patrys?

Wall Street analysts have given Patrys a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Patrys wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Patrys' earnings last quarter?

Patrys Limited (ASX:PAB) issued its quarterly earnings results on Wednesday, February, 20th. The company reported $0.00 earnings per share (EPS) for the quarter.
View Patrys' earnings history.

Who are Patrys' key executives?

Patrys' management team includes the following people:

Dr. James A. Campbell B.Sc., Ph.D., MBA, MD, CEO & Exec. Director
Ms. Melanie Jaye Leydin C.A., B.Bus, CA, Company Sec. (Age 48, Pay $120k)
Dr. Deanne Greenwood B.Sc., GAICD, Ph.D., MBA, VP of Bus. Devel. & Intellectual Property

Who are some of Patrys' key competitors?

Some companies that are related to Patrys include Antisense Therapeutics (ANP), Bayer Aktiengesellschaft (BAYN), Mayne Pharma Group (MAYNF), Mayne Pharma Group (MYX), Medical Developments International (MVP), Opthea (OPT), Otsuka (OTSKY), Pharmaxis (PXS), Recce Pharmaceuticals (RCE), Roche (RHHVF), Sanofi (SNYNF), Sanofi (SAN), Sinclair Pharma (SPH) and Vita Life Sciences (VLS).
View all of PAB's competitors.

What other stocks do shareholders of Patrys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Patrys investors own include Woolworths Group (WOW), Proteomics International Laboratories (PIQ), Insurance Australia Group (IAG) and Bendigo and Adelaide Bank (BEN).

What is Patrys' stock symbol?

Patrys trades on the ASX under the ticker symbol "PAB."

How much money does Patrys make?

Patrys has a market capitalization of $0.00 and generates $1.34 million in revenue each year.

What is Patrys' official website?

The official website for Patrys is www.patrys.com.

How can I contact Patrys?

The company can be reached via phone at 61 3 9692 7222.

This page was last updated on 9/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.